More MS news articles for August 2002

Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome

Journal of Neuroimmunology, Vol. 129 (1-2) (2002) pp. 232-236
S. Dubucquoi a, J. de Seze a,b, D. Lefranc a, L. Almeras a, V. Dutoit a, L. Prin a and P. Vermersch b
a Department of Immunology, CHRU of LILLE, 1 place de Verdun, 59045 Lille cedex, France
b Department of Neurology, CHRU of LILLE, Lille, France

We investigated the effects of interferon beta-1a (IFN b-1a) on specific response towards two immunodominant MBP peptides and on global production of IgG.

We evaluated 54 sera from multiple sclerosis (MS) patients at baseline and 1 year after treatment.

We did not observe any modification of immune response to the MBP peptides but we noted a significant decrease in mean IgG concentrations in patients with progression of the disease but not in stable patients.

These results suggest that IFN b1a restores or maintains a beneficial immune response.

© 2002 Elsevier Science B.V.